Champions Oncology (CSBR) vs Tenaya Therapeutics (TNYA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Champions Oncology (CSBR) has outperformed Tenaya Therapeutics (TNYA) over the past year, losing 35.9% versus a loss of 76.7%. Over five years, CSBR leads with a -53.0% price change compared with -98.5% for TNYA. Tenaya Therapeutics is the larger company by market cap ($65.3 million vs $60.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CSBR | TNYA |
|---|---|---|
| Share price | $4.34 | $0.2866 |
| Market cap | $60.41M | $65.32M |
| 1-day change | -1.36% | -3.99% |
| YTD return | -37.19% | -59.75% |
| 1-year return | -35.89% | -76.70% |
| 5-year return | -52.98% | -98.50% |
| Forward P/E | 43.40 | — |
| EPS (TTM) | $-0.07 | $-0.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $59.42M | — |
| Revenue growth (YoY) | +4.36% | — |
| Net income (latest FY) | $-1.18M | $-90.60M |
| Gross margin | 48.00% | — |
| Operating margin | -1.92% | — |
| Net margin | -1.98% | — |
| 52-week high | $8.31 | $1.46 |
| 52-week low | $4.34 | $0.28 |
| Distance from 52-week high | -47.77% | -80.37% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +1016.54% |
| Average volume | 9.71K | 2.96M |
| Shares outstanding | 13.92M | 227.93M |
| Employees | 214 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CSBR has outperformed TNYA by 40.8 percentage points over the past year.
About Champions Oncology
CSBR stock →Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 214 employees
About Tenaya Therapeutics
TNYA stock →Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 70 employees
CSBR vs TNYA FAQ
Which is bigger, Champions Oncology or Tenaya Therapeutics?
Tenaya Therapeutics (TNYA) is larger, with a market capitalization of $65.32M compared with $60.41M for Champions Oncology (CSBR).
Which stock has performed better over the past year, CSBR or TNYA?
CSBR returned -35.89% over the past 12 months, compared with -76.70% for TNYA (price return, excluding dividends). Past performance does not predict future results.
Are Champions Oncology and Tenaya Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.